Direction
Buy
Sell
Types
LMT Order
Price
QTY
Amount
--
PEAR Pear Therapeutics
1.090+0.010+0.93%
Close
01/31 16:00 ET
1.120+0.030+2.75%
Post Mkt Price 01/31 19:34 ET
High
1.150
Open
1.100
Turnover
150.06K
Low
1.080
Pre Close
1.080
Volume
136.21K
Post-Market
5D
1D
1W
1M
1Q
1Y
Price Forecast
News
Comment
Pear Therapeutics Expands Program With Brightview on Prescription Digital Therapeutics
Pear Therapeutics' Two Addiction Treatments Get on Florida's Medicaid Preferred Drug List
03:05 PM EST, 01/18/2023 (MT Newswires) -- Pear Therapeutics (PEAR) said Wednesday its prescription digital therapeutics reSET and reSET-O will be on the January 2023 Florida Medicaid Preferred Drug L
Pear Therapeutics Announces Inclusion Of ReSET And ReSET-O On The January 2023 Florida Medicaid Preferred Drug List
Pear's prescription digital therapeutics (PDTs), reSET and reSET-O, are included on the January 2023 Florida Medicaid Preferred Drug List (PDL), effective January 1, 2023Florida Medicaid is covering r
Pear Therapeutics Wins Contract to Assist California's Stimulant Use Disorder Recovery Program
09:06 AM EST, 01/12/2023 (MT Newswires) -- Pear Therapeutics (PEAR) said Thursday that the California Department of Health Care Services, or DHCS, has picked the company to assist in the execution of
Pear Selected by California DHCS to Support Recovery Incentives Program
California Department of Health Care Services Awards Contract to Pear Therapeutics to Support the Recovery Incentives Program
The California Department of Health Care Services (DHCS) selected Pear Therapeutics to track and distribute incentives for the groundbreaking Recovery Incentives: California's Contingency Management
Pear to Use COEUS Healthcare Value-based Contracting for Prescription Digital Therapeutics
Pear Therapeutics, Spero Expand Partnership for Digital Therapeutics for Substance Use
Pear Expands Collaboration With Spero Health to Treat Adults With SUD
Pear Therapeutics Inc Files For Mixed Shelf Of Up To $300M
Pear Therapeutics Inc Files For Mixed Shelf Of Up To $300M
Company Overview
More
Pear Therapeutics, Inc.( formerly Thimble Point Acquisition Corp. ) is a commercial-stage healthcare company pioneering a new class of software-based medicines, sometimes referred to as Prescription Digital Therapeutics (PDT), which use software to treat diseases directly. The firm aims to redefine medicine by discovering, developing, and delivering clinically validated software-based therapeutics to provide better outcomes for patients, smarter engagement and tracking tools for clinicians, and cost-effective solutions for payers. It has a pipeline of products and product candidates across therapeutic areas, including the first three PDTs with disease treatment claims from the FDA. The company’s lead product, reSET, for the treatment of substance use disorder, was the first PDT to receive marketing authorization from the FDA to treat disease. Its second product, reSET-O, for the treatment of opioid use disorder, was the first PDT to receive Breakthrough Designation. Pear's third product, Somryst for the treatment of chronic insomnia, was the first PDT submitted through the FDA's traditional 510(k) pathway while simultaneously reviewed through the FDA's Software Precertification Pilot Program. The company was founded on December 1, 2020 and is headquartered in Boston, MA.
CEO： Dr. Corey McCann, Pd.D
Market： NASDAQ
Listing Date： 02/02/2021
Paper Trade
More
Hot List
TradeSearchNews
SymbolLatest price%Chg
Loading...
Watchlist
No Stock Yet